444 results about "Epsilon-caprolactone" patented technology

The invention relates to a mixture of biodegradable polyesters comprising: (A) a polyhydroxy acid of the poly-epsilon-caprolactone type and its copolymers, (B) aliphatic polyester, and (C) a polymer of polylactic acid, in which the concentration of (A) varies with respect to (A+B) in the range between 40 and 70% by weight, and the concentration of (C) with respects to (A+B+C) lies between 2 and 30%.

The present invention relates to biodegradable polymer compositions comprising poly(lactic acid) and poly(epsilon caprolactone) mixed with organic peroxide and magnesium silicate minerals. In addition, the present invention relates to films, coatings and products made on the basis of said compositions and to a method for their preparation.

A medicine eluted cardiovascular frame is composed of expandible support and the medicine coated biodegradable layer coated on the said frame. The said biodegradable material contains one of the homopolymer and copolymer of glycollide, L-lactide or epsilon-caprolactone, and the copolymer of multi-group amino acids. The medicine can resist the cardiovascular narrowness. The process for preparing the said support includes such steps as preparing the said expandible support, immersing it in the mixture of the said medicine, biodegradable material and solvent, and drying. It can prevent thrombosis.

In on aspect, the invention includes a microcarrier bead having a porous three-dimensional core having (a) a polymeric porous three-dimensional body having porosity of about 15 to about 90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns, (b) an outer protective layer and optionally (c) a filler. In another aspect, the invention includes a method of making an artificial scaffold wherein a scaffolding material is extruded into a coolant and thereby creating a porous material having a porosity of between 15-90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns.

The invention relates to a polylactic acid degradable film with controllable degradable time, belonging to the technical field of medical appliances. The polylactic acid degradable film comprises the following components in percentage by weight: 1%-35% of plasticizer and 65%-99% of polylactic acid, polylactic acid-glycollic acid copolymer, polyglycollic acid-epsilon-caprolactone copolymer, polylactic acid-epsilon-caprolactone copolymer or polylactic acid-glycollic acid-epsilon-caprolactone copolymer, wherein the plasticizer is more than one of citrate ether, glucose monoester ether, fatty acid ester ether, polyethylene glycol 400-2,000, low-molecular weight polylactic acid, glycerol, glycerol triacetate and ethylene glycol monobutyl ether acetate. The manufactured polylactic acid degradable film of the invention has good strength and controllable degradable time, can be used for a human body, such as an anti-adhesion film in a surgical operation, a digestive stent, a biliary stent, a prostate stent, an endovascular stent, an intrauterine stent and a medical appliance fitting, and can be used for preparing the required controllable polylactic acid degradable film according to the clinical requirements.

Disclosed is a biocompatible medical material and porous scaffold for use in tissue engineering, made from a biodegradable glycolide/ε-caprolactone copolymer having a repeat unit of

wherein x and y are integers greater than or equal to 18, the copolymer has an average molecular weight of about 10,000 daltons or more, and the molar ratio of glycolide: ε-caprolactone in the copolymer is about 4.0:6.0 to 6.0:4.0.

The invention relates to a degradable and nontoxic medical polyurethane material and a preparation method thereof, belonging to the technial field of biomedical high polymer materials. Raw materials thereof adopt poly (epsilon-caprolactone) dibastic alcohol (PCL) as a soft segment and L-lysine ethyl ester diisocyanate (LDI-E) or L-lysine methyl ester diisocyanate (LDI-M) and chain extender L-lysine ethyl ester (Lysine-E) or L-lysine methyl ester (Lysine-M) as a hard segment, wherein the number-average molecular weight of the poly (epsilon-caprolactone) dibastic alcohol ranges from 500 to 5000.The polyurethane of the invention is degradable, and degradation products thereof are harmless to human bodies; as a great amount of carbamido is contained in the polyurethane, the mechanical property and the degradation property of the polyurethane are improved; and the degradation products are completely nontoxic, the degradation product of lysine can neutralize 6- hydroxyl hexanoic acid generated by soft segment degradation, the pH value of adjacent tissues can not be changed, and therefore the polyurethane prepared by the invention has favorable biocompatibility.

The invention relates to a polyacrylate modified water-based enclosed isocyanate curing agent and a preparation method thereof. The curing agent is obtained by neutralizing and emulsifying a prepolymer formed by polyisocyanate semi-enclosed object and hydroxyl-containing polyacrylate, and the mole ratio of NCO to OH is 1-1.15:1. The hydroxyl-containing polyacrylate is prepared by: taking 10-50wt% of a solvent as the base material, and dripping a mixture composed of 5-15% of a carboxyl-containing vinyl monomer, 2-20% of a primary hydroxyl or secondary hydroxyl-containing acrylate monomer, 1-10% of a primary hydroxyl-containing epsilon-caprolactone modified vinyl monomer, 5-70% of other monomer containing a vinyl structure, 0.1-5% of a chain transfer agent and 0.05-3% of an initiator into the base material. The sealant and polyisocyanate for preparation of the polyisocyanate semi-enclosed object are in a mole ratio of 1.05-1.5:1. The curing agent has good miscibility with the matrix resin, high curing efficiency, low cost, flexibility and impact resistance.

The invention discloses a hydroxylapatite/biodegradable polyester composite material and a preparation method thereof. The preparation method includes the following steps: under conditions of no water, no oxygen, and argon protection, the composite material is obtained by carrying out an in-situ polymerization reaction of hydroxyapatite and an aliphatic cyclic monomer under catalysis of stannous octoate; the aliphatic cyclic monomer is selected form at least one of lactide, epsilon-caprolactone and glycolide; and the composite material provided by the invention comprises hydroxylapatite and a biodegradable polyester. The composite material provided by the invention has the surface enriched with a hydroxylapatite layer having a biological activity, and has an excellent biological compatibility and the biological activity; an biological activity interface can rapidly induce calcium ion deposition in a physiological environment so as to induce nucleation and growth of apatite, and imitates inorganic/organic components of a natural bone matrix in composition; based on the above characteristics, the modified hydroxylapatite/biodegradable polyester composite material is a good support material for repairing bone defects, and has good application prospects in the fields of cell expansion and bone tissue engineering.

The invention relates to a nanomicelle of magnetic tumor double-targeting polymer and a preparation method thereof. The nanomicelle of magnetic tumor double-targeting polymer is a nuclear shell structure; the surface of an outer shell is connected with targeted ligand, an inner core is enclosed with nano-particles of super paramagnetic ferriferrous oxide and anticarcinogen with hydrophobic property; in virtue of the physical effect of an external magnetic field and induction of the targeting ligand, the tumor double-targeting function of the nanomicelle is realized. The invention also provides the preparation method of the nanomicelle of magnetic tumor double-targeting polymer: polyethylene glycol with end capping by folacin, and poly Epsilon-caprolactone or sandwich copolymer of poly propiolactone are taken as raw materials and enclosed with the nano-particles of super paramagnetic ferriferrous oxide and the anticarcinogen with hydrophobic property, and then dialysed to obtain the nanomicelle of magnetic tumor double-targeting polymer. The drug carrier system of the nanomicelle reinforces the treatment effect of the anticarcinogen with hydrophobic property on tumor, prolongs the circulating time of the anticarcinogen in human body, intensifies the targeting action of drugs, improves the release efficiency and partial concentration of drugs, and reduces the dosage and toxic and side effect of drugs.

A co-polyester which includes the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol. The co-polyester is injectable and absorbable into animal, such as human, tissue and can be used for facial cosmetic or reconstructive surgery of soft tissue. Another embodiment is directed to a method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol, and the co-polyester comprises about 40 to 50% by weight of the polycondensation polyester based on the total weight of the co-polyester.

The present invention relates to one kind of biodegradable medical extracorporeal fixing material with shape memory function. The material is polylactic acid and may have added copolymer of epsilon-caprolactone and lactide-epsilon-caprolactone, inorganic mineral, silane as cross-linking agent, coloring agent and other components. It may produced into plate through mixing, pelletizing, extruding, rolling and other steps; or into netted structure through mixing, pelletizing, extruding, weaving and other steps. When it is used, the biodegradable medical extracorporeal fixing material is first softened in warm water at 55-70 deg.c, then fixed in the required position and finally hardened after the temperature is lowered to room temperature. The present invention has excellent permeability, good water tolerance, high strength, shape memory function, capacity of being reused, no irritation to skin, degradability and other advantages.

The invention provides the usage of using the benzoic acid stannous as catalyst. The invention solves the problem that polymerization rate of current catalyst in lactic acid and glycolic acid is slow. The benzoic acid stannous is the catalyst used for preparing low-molecular polymer lactic acid with lactic acid dewatering; benzoic acid stannous is the catalyst used for preparing lactide with low-molecular polymer lactic acid cracking; benzoic acid stannous is the catalyst used for preparing polylactic acid with lactide polymerizing; benzoic acid stannous is the catalyst used for preparing low-molecular polymer glycolic acid with glycolic acid dewatering; benzoic acid stannous is the catalyst used for preparing glycolide with low-molecular polymer glycolic acid cracking; benzoic acid stannous is the catalyst used for preparing poly-glycollide with glycolide polymerizing. The benzoic acid stannous is the catalyst used for polymerizing glycolide, lactide and epsilon-caprolactone. Using the benzoic acid stannous is low content, high productivity, high product purity, low temperature and good repeatability.

The invention relates to method of preparing secondary functionalization organic modified montmorillonite (TFC), toughening and reinforcement biodegradable polylactic acid nano composite material using the organic montmorillonite and preparing method thereof. The novel double-function group organic modified montmorillonite (TFC) enhances adhesion force between montmorillonite and polymer molecule and obviously increases property of the composite material. The toughening and reinforcement biodegradable polylactic acid nano composite material is prepared by using polylactic acid as main raw material, and adding certain poly(epsilon-caprolactone) and lactic acid-epsilon-caprolactone copolymer; plasticizer selects acetyl tri-n-butyl citrate, tri-n-butyl citrate, triethyl citrate, dioctyl phthalate, and dibutylphthalate; lubricant selects aluminum stearate and calcium stearate; heat stabilizer selects maleic anhydride and epoxy soybean oil (EOS); and intensifier selects TFC montmorillonite (MMT). The prepared composite material possesses high strength and good toughness, and is hopeful of replacing traditional non-degradable material to be applied in field such as packaging, medical, and engineering for solving environment problems generated by white pollution.

It is intended to provide a lactide/epsilon-caprolactone copolymer for a flexible medical implant which has extremely high safety without containing a higher alcohol and is useful for producing a medical implant required to have flexibility such as artificial dura mater or artificial blood vessel. Further, it is intended to provide a method for producing the copolymer, a medical implant and artificial dura mater comprising the copolymer. The invention is directed to a lactide/e-caprolactone copolymer to be used for medical implant application, wherein a molar ratio of lactide to e-caprolactone (lactide/e-caprolactone) is from 40/60 to 60/40, a weight average molecular weight is 100,000 to 500,000 or less, a higher alcohol component is not contained, and a melting enthalpy of crystal obtained by heat-melting the copolymer to form a molded article is 10 J/g or less.

Disclosed is a biodegradable sheet comprising at least one layer which is a direct contact layer, intended to successfully contact materials, such as liquids, while maintaining the mechanical properties of the sheet and to extend the biodegradable sheet shelf life. The direct contact layer may comprise a hydrophobic polymer selected from poly(epsilon-caprolactone) (PCL) polyhydroxybutyrate (PHB), Polydioxanone (PDO) polyglycolic acid (PGA), polybutylene succinate (PBS), polybutylene succinate adipate (PBS A), poly lactic acid (PL A), polybutylene adipate terphtalate (PBAT), polyhydroxyalkanoates (PHA), such as polyhydroxybutyrates (PHB), polyhydroxyvalerates (PHV), and polyhydroxybutyrate-hydroxyvalerate copolymers (PHBV) or any mixture thereof. The biodegradable sheet may further comprise surface treated nanoclay particles, PVOH grafted with a crosslinker and PBS or PBS A The biodegradable sheet may further include at least one metalized, biodegradable, laminate layer.

The invention discloses a regular structure multi-block biodegradable thermic shape memory polymer and a preparation method thereof. The shape memory polymer consists of a plurality of soft blocks and hard blocks which are alternately arranged. The soft blocks and the hard blocks are both copolymers and both have even chain length; the content of the hard blocks is between 50 and 90 weight percent; and the content of the soft blocks is between 10 and 50 weight percent. Each soft block is a crystalline poly(epsilon-caprolactone-glycolide)chain segment which has the fusion point 3 DEG C above a body temperature; and each hard block is a crystalline poly(L-lactide-glycolide)chain segment which has the fusion point 50 DEG C above the body temperature and a controllable deformation recovery rate. The shape memory polymer can relatively independently control the mechanical properties and the degradation rate, thereby having the mechanical properties and the controllable degradation rate matched with the implanted tissue in vivo. With good forming machining performance and excellent biocompatibility, the shape memory polymer can be used as a new functional biological medical material. The preparation method is characterized by simplicity, short reaction time, no residual harmful reagent content, and the like, thereby facilitating the commercialization.

The invention discloses a method for preparing caprolactone and adipic acid. The method is characterized in that a soluble zinc salt-modified silicon molecular sieve is utilized as a catalyst; cyclohexanone, oxidants, solvents and the catalyst undergo a reaction under the conditions of a temperature of 40 to 150 DEG C and pressure of 0.1 to 3MPa, wherein in the reaction, a molar ratio of cyclohexanone to the oxidants is 1: (1 to 20) and a mass ratio of the solvents to the catalyst is (1 to 200): 1; caprolactone and adipic acid are obtained simultaneously after separation of the reaction products; and unreacted cyclohexanone and the like can be recycled directly without purification separation. Under the condition of high total selectivity of epsilon-caprolactone and adipic acid, the method can realize a high effective utilization rate of an oxidant, and good catalytic oxidation activity and catalytic activity stability.

The invention discloses a method for preparing epsilon-caprolactone, under the condition that solid acid catalyst exists, peroxide carboxylic acid solution is obtained by using hydrogen peroxide to oxidate organic carboxylic acid in a stirring reactor which has a fractionating column, the obtained peroxide carboxylic acid solution is reacted with cyclohexanone to obtain epsilon-caprolactone solution, then the high-purity epsilon-caprolactone is obtained after distillation and purification.

The invention discloses a ureteral stent tube made of a degradable material. The stent tube is a double-layer compound tube, the inner layer is constituted by a L-lactide/epsilon-caprolactone copolymer (PLLCA) elastomer material, and the weight average molecular weight of an L-lactide/epsilon-caprolactone copolymer is 0.1-0.8 million, wherein an epsilon-caprolactone unit accounts for 15%-25% in the copolymer, an L-lactide unit accounts for 75%-85%, and a layer of poly-1,4-dioxanone (PPDO) is uniformly covered on the outer layer of the ureteral stent tube. The viscosity average molecular weight is 0.1-0.5 million. The ureteral stent tube has the advantages of being good in biocompatibility, being capable of realizing self-degradation, being capable of being degraded and excreted from a body without drawing the tube, and reducing suffering and economic burden of a patient.

The invention relates to a method for preparing epsilon-caprolactone by virtue of catalytic oxidation of cyclohexanone. The method comprises the following steps: S1, according to the use amount determined in advance, adding a raw material (anhydride) into a reaction container filled with a raw material (aqueous hydrogen peroxide solution) and a catalyst, and controlling the temperature of a reaction system at 5-20 DEG C so as to prepare organic peracid; and S2, adding the generated organic peracid into the cyclohexanone, evenly mixing, controlling the temperature of the reaction system at 30-100 DEG C, continuously reacting for 1-15 hours, cooling and separating after reaction is finished so as to obtain the finished epsilon-caprolactone. According to the method, in the catalytic oxidation process, the selectivity of the catalyst and the yield of the epsilon-caprolactone are still improved even though water exists in the reaction system; in the reaction process, the water in the reaction system dose not need to be removed, thus the reaction condition is reduced so that the reaction process is mild and is easy to control; the reaction is high in safety and environmentally-friendly while the high yield and selectivity can be achieved, and the used catalyst is cheap and available, is easy to prepare, has no halogen elements and is high in stability.

The present invention discloses one kind of medical ureter rack tube made of absorbable material. The absorbable material is epsilon-caprolactone-lactide copolymer or the copolymer of epsilon-caprolactone and lactide and/or diglycolide of molecular weight 50-800 KD, where epsilon-caprolactone accounts for 10-80 wt% of the copolymer and the lactide is DL-lactide or L-lactide. The absorbable material for ureter rack tube has excellent biocompatibility, can degrade automatically and may be exhausted out after degrading with less pain and burden.

The invention relates to a dust prevention and sand fixation method. The method comprises the following steps: diluting a polyurethane type ecological sand-fixing agent with water, wherein the concentration by weight percent of a polyurethane prepolymer is 0.5-5%; and then spraying dilution solution of the sand-fixing agent onto sandy soil for forming a solidified layer on the surface layer of the sandy soil, wherein the active ingredient of the polyurethane type ecological sand-fixing agent is the polyurethane prepolymer, the polyurethane prepolymer is obtained by condensation polymerizationbetween a polymer polyol and a diisocyanate compound, the polymer polyol comprises polyoxypropylene diol, polyethyleneoxide diol and easily degradable polymer diol, the mass ratio of the polyoxypropylene diol to the polyethyleneoxide diol is 1:3-5:1 and the easily degradable polymer diol accounts for 13-23% of the total weight of the polymer polyol; and the mass ratio of the polymer polyol to thediisocyanate compound is 4:1-7:1, and the easily degradable polymer diol is epsilon-caprolactone, polylactic acid diol or a mixture of epsilon-caprolactone and polylactic acid diol in any proportion.